Cellares, which last year became the first company to receive the FDA's new advanced manufacturing technology designation, ...

UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes ...

Magnetic nanoparticles engineered T cells inside living mice and guided them into solid tumors, achieving over 90% tumor ...

Cellares recently announced that Cabaletta Bio’s investigational CAR T therapy rese-cel received FDA clearance of an IND ...

ASH 2025 data on KLN-1010 suggest that off-the-shelf, in vivo CAR T therapy could significantly expand access to cellular ...

Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain ...

Universal gene‑edited CAR‑T therapies turn donor T cells into off‑the‑shelf cancer treatments, cutting delays and costs while ...

Orphan drug designation is granted by the FDA for therapies treating rare disease affecting fewer than 200,000 patients in the U.S., and provides development incentives including extended market ...

Cellares and City of Hope announced a collaboration Jan. 8 to evaluate automated manufacturing for an investigational CAR T cell therapy. The effort will target glioblastoma multiforme, a fast-growing ...

Efforts to develop off-the-shelf (OTS) cell therapies are accelerating across global biotech, as researchers aim to make next-generation cancer treatments more accessible, affordable, and consistent.

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Imviva Biotech's CTD402 to accelerate the ...

Discover how platformed lentiviral manufacturing and ready-to-deploy CAR-T solutions are breaking the critical barriers of ...